HIV-specific broadly neutralizing antibodies may be able to prevent virus emerging from latent reservoir sites from entering CD4 T-cells, as well as suppressing viral replication if HIV does manage to get in, according to NIAID research published in the August 25 advance edition of Proceedings of the National Academy of Sciences.
There are significant losses at each step of the post-exposure prophylaxis (PEP) "treatment cascade," according to a systematic review and meta-analysis of 97 studies presented to the 20th International AIDS Conference last month in Melbourne. The problems with uptake, adherence, and completion point to a need for a simplified approach, researchers said.
An additional 2 people with long-term HIV infection have no evidence of infectious virus or viral genetic material following bone marrow stem cell transplants to treat leukemia or lymphoma, researchers reported at the 20th International AIDS Conference last month in Melbourne. While these individuals remain on antiretroviral therapy (ART) and therefore cannot be considered functionally cured, they offer further evidence that HIV may be controlled off ART in some cases.
While biomedical HIV prevention was a key theme of the recent 20th International AIDS Conference in Melbourne, other approaches remain important including wider access to internal or female condoms. Designed to be worn inside the body, female condoms can give women more control in protecting themselves against HIV.